Recent Finacing
Recent Raise
Sitka Biopharma is a UBC/CDRD spin‑off developing an HPG‑docetaxel nanoparticle platform to enhance tissue uptake, advancing STK‑01 for intravesical bladder cancer and intraperitoneal delivery into GMP/GLP and Phase 1.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Sitka Biopharma.
